Gene therapy for hemophilia
- 27 October 2017
- journal article
- review article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 65 (2)
Abstract
Individuals with the inherited bleeding disorder hemophilia have achieved tremendous advances in clinical outcomes through widespread implementation of prophylactic replacement with safe and efficacious factor VIII and IX. However, despite this therapeutic approach, bleeds still occur, some with serious consequence, joint disease has not been eradicated, and patients have not yet been liberated from the need for regular intravenous infusions. The shift from protein replacement to gene replacement is offering great hope to achieve durable levels of plasma factor activity levels high enough to remove the risk for recurrent joint bleeding. For the first time, clinical trial results are showing promise for “curative” correction of the bleeding phenotype.Keywords
This publication has 50 references indexed in Scilit:
- Immune responses to AAV vectors: overcoming barriers to successful gene therapyBlood, 2013
- Generation of an optimized lentiviral vector encoding a high-expression factor VIII transgene for gene therapy of hemophilia AGene Therapy, 2012
- Guidelines for the management of hemophiliaHaemophilia, 2012
- Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia BNew England Journal of Medicine, 2011
- Haemophilia: provision of factors and novel therapies: World Federation of Hemophilia goals and achievementsBritish Journal of Haematology, 2011
- Treatment of hemophilia: a review of current advances and ongoing issuesJournal of Blood Medicine, 2010
- Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe HemophiliaNew England Journal of Medicine, 2007
- International workshop on immune tolerance induction: consensus recommendations1Haemophilia, 2007
- The Hemophilias — From Royal Genes to Gene TherapyNew England Journal of Medicine, 2001
- Human factor VIII can be packaged and functionally expressed in an adeno‐associated virus background: applicability to haemophilia A gene therapyBritish Journal of Haematology, 1999